Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, ß-lapachone (ARQ761...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Autores principales: Chakrabarti, Gaurab, Silvers, Molly A., Ilcheva, Mariya, Liu, Yuliang, Moore, Zachary R., Luo, Xiuquan, Gao, Jinming, Anderson, Glenda, Liu, Lili, Sarode, Venetia, Gerber, David E., Burma, Sandeep, DeBerardinis, Ralph J., Gerson, Stanton L., Boothman, David A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4658501/
https://ncbi.nlm.nih.gov/pubmed/26602448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep17066
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares